Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.
暂无分享,去创建一个
R. Stevens | I. D. de Esch | R. Leurs | V. Katritch | C. de Graaf | S. Iwata | H. Vischer | M. Shiroishi | A. Kooistra | T. Shimamura | M. Kuijer
[1] Didier Rognan,et al. Fragment-based approaches and computer-aided drug discovery. , 2012, Topics in current chemistry.
[2] Krzysztof Palczewski,et al. The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery , 2011, Pharmacological Reviews.
[3] Ruben Abagyan,et al. GPCR agonist binding revealed by modeling and crystallography. , 2011, TIPS - Trends in Pharmacological Sciences.
[4] R. Smits,et al. Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A , 2011, Bioorganic & medicinal chemistry letters.
[5] Ruben Abagyan,et al. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. , 2011, Structure.
[6] Avner Schlessinger,et al. Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.
[7] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[8] Jean-Louis Reymond,et al. Visualisation and subsets of the chemical universe database GDB-13 for virtual screening , 2011, J. Comput. Aided Mol. Des..
[9] Jonathan S. Mason,et al. Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.
[10] Didier Rognan,et al. Docking Methods for Virtual Screening: Principles and Recent Advances , 2011 .
[11] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[12] Erica Westly. Nothing to sneeze at , 2010, Nature Medicine.
[13] Mathias Wawer,et al. Similarity-Potency Trees: A Method to Search for SAR Information in Compound Data Sets and Derive SAR Rules , 2010, J. Chem. Inf. Model..
[14] Wen Jiang,et al. Molecular Determinants of Ligand Binding to H4R Species Variants , 2010, Molecular Pharmacology.
[15] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[16] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[17] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[18] Didier Rognan,et al. Customizing G Protein-coupled receptor models for structure-based virtual screening. , 2009, Current pharmaceutical design.
[19] Thomas M Frimurer,et al. A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-transmembrane Receptors* , 2009, The Journal of Biological Chemistry.
[20] A. Brown,et al. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist. , 2009, Bioorganic & medicinal chemistry letters.
[21] Jason C. Cole,et al. Testing Assumptions and Hypotheses for Rescoring Success in Protein-Ligand Docking , 2009, J. Chem. Inf. Model..
[22] Rob Leurs,et al. Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.
[23] Sid Topiol,et al. X-ray structure breakthroughs in the GPCR transmembrane region. , 2009, Biochemical pharmacology.
[24] S. Rasmussen,et al. The structure and function of G-protein-coupled receptors , 2009, Nature.
[25] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[26] Andreas Evers,et al. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. , 2009, Journal of medicinal chemistry.
[27] Wendy A. Warr,et al. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..
[28] Thierry Kogej,et al. Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data , 2009, J. Chem. Inf. Model..
[29] Thomas Stützle,et al. Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..
[30] The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. , 2008, Bioorganic & medicinal chemistry letters.
[31] Kenneth Jones,et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.
[32] D. Rognan,et al. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.
[33] Béla Noszál,et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[34] Chris G. Kruse,et al. Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.
[35] R. Gillespie,et al. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. , 2008, Bioorganic & medicinal chemistry letters.
[36] Didier Rognan,et al. Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..
[37] H. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[38] Stefano Costanzi,et al. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.
[39] Ajay N. Jain,et al. Recommendations for evaluation of computational methods , 2008, J. Comput. Aided Mol. Des..
[40] Stefano Costanzi,et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.
[41] Claudio N. Cavasotto,et al. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[42] Jan Schultz,et al. Integration of fragment screening and library design. , 2007, Drug discovery today.
[43] Vladimir Sobolev,et al. Target specific virtual screening: optimization of an estrogen receptor screening platform. , 2007, Journal of medicinal chemistry.
[44] Thomas Stützle,et al. An ant colony optimization approach to flexible protein–ligand docking , 2007, Swarm Intelligence.
[45] R. Leurs,et al. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists , 2007, Journal of Pharmacology and Experimental Therapeutics.
[46] E. Kellenberger,et al. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.
[47] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[48] Raphael Nudelman,et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. , 2006, Journal of medicinal chemistry.
[49] Cathy H. Wu,et al. The Universal Protein Resource (UniProt): an expanding universe of protein information , 2005, Nucleic Acids Res..
[50] Didier Rognan,et al. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.
[51] Rob Leurs,et al. Keynote review: histamine H3 receptor antagonists reach out for the clinic. , 2005, Drug discovery today.
[52] Tudor I. Oprea,et al. Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.
[53] Antti Poso,et al. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. , 2005, Journal of medicinal chemistry.
[54] L. Pardo,et al. Linking agonist binding to histamine H1 receptor activation , 2005, Nature chemical biology.
[55] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[56] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[57] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[58] D. E. Clark,et al. A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. , 2004, Journal of medicinal chemistry.
[59] D. J. Price,et al. Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.
[60] R. Leurs,et al. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens. , 2004, European journal of pharmacology.
[61] Xueliang Fang,et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.
[62] Jun Xu. A new approach to finding natural chemical structure classes. , 2002, Journal of medicinal chemistry.
[63] R. Leurs,et al. H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[64] M. Gillard,et al. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). , 2002, Molecular pharmacology.
[65] Lei Shi,et al. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.
[66] R. Leurs,et al. Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor* , 1999, The Journal of Biological Chemistry.
[67] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[68] H Hayashi,et al. Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. , 1994, Biochemical and biophysical research communications.
[69] S. Takai,et al. Molecular cloning of the human histamine H1 receptor gene. , 1994, Biochemical and biophysical research communications.
[70] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.